LONGEVA.

PXL770: adverse events and evidence limits

An oral PXL770 trial in nonalcoholic fatty liver disease, assessed at week 12, reported diarrhea as the most frequent treatment-emergent event. Treatment-emergent adverse events overall occurred in all arms, including placebo. [1]

The abstract, rather than complete safety tables, was read. Dose groups were not pooled; another preparation’s safety is not established. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
DiarrheaPatients with nonalcoholic fatty liver disease, oral PXL770, assessed at week 12The most frequent treatment-emergent event in the abstract; no percentage given, and complete safety tables were not read[1]
Treatment-emergent adverse events overallThe same patients, all trial armsOccurred in all arms, including placebo; dose groups were not pooled[1]

References

  1. Kenneth Cusi et al. (2021). Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study https://doi.org/10.1016/S2468-1253(21)00300-9.